205 related articles for article (PubMed ID: 31515079)
1. Aldehyde Dehydrogenase Inhibitors for Cancer Therapeutics.
Dinavahi SS; Bazewicz CG; Gowda R; Robertson GP
Trends Pharmacol Sci; 2019 Oct; 40(10):774-789. PubMed ID: 31515079
[TBL] [Abstract][Full Text] [Related]
2. Aldehyde dehydrogenases in cancer: an opportunity for biomarker and drug development?
Pors K; Moreb JS
Drug Discov Today; 2014 Dec; 19(12):1953-63. PubMed ID: 25256776
[TBL] [Abstract][Full Text] [Related]
3. Aldehyde dehydrogenases and cell proliferation.
Muzio G; Maggiora M; Paiuzzi E; Oraldi M; Canuto RA
Free Radic Biol Med; 2012 Feb; 52(4):735-46. PubMed ID: 22206977
[TBL] [Abstract][Full Text] [Related]
4. Targeting aldehyde dehydrogenase enzymes in combination with chemotherapy and immunotherapy: An approach to tackle resistance in cancer cells.
Al-Shamma SA; Zaher DM; Hersi F; Abu Jayab NN; Omar HA
Life Sci; 2023 May; 320():121541. PubMed ID: 36870386
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis characterization and biological evaluation of novel multi-isoform ALDH inhibitors as potential anticancer agents.
Dinavahi SS; Gowda R; Bazewicz CG; Battu MB; Lin JM; Chitren RJ; Pandey MK; Amin S; Robertson GP; Gowda K
Eur J Med Chem; 2020 Feb; 187():111962. PubMed ID: 31887569
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44⁺ human breast cancer cells.
Croker AK; Allan AL
Breast Cancer Res Treat; 2012 May; 133(1):75-87. PubMed ID: 21818590
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases.
Khanna M; Chen CH; Kimble-Hill A; Parajuli B; Perez-Miller S; Baskaran S; Kim J; Dria K; Vasiliou V; Mochly-Rosen D; Hurley TD
J Biol Chem; 2011 Dec; 286(50):43486-94. PubMed ID: 22021038
[TBL] [Abstract][Full Text] [Related]
8. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.
Koppaka V; Thompson DC; Chen Y; Ellermann M; Nicolaou KC; Juvonen RO; Petersen D; Deitrich RA; Hurley TD; Vasiliou V
Pharmacol Rev; 2012 Jul; 64(3):520-39. PubMed ID: 22544865
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents: Kinetic characterization and effect on human cancer cells.
Jiménez R; Pequerul R; Amor A; Lorenzo J; Metwally K; Avilés FX; Parés X; Farrés J
Chem Biol Interact; 2019 Jun; 306():123-130. PubMed ID: 30958995
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial aldehyde dehydrogenase, a potential drug target for protection of heart and brain from ischemia/reperfusion injury.
Luo XJ; Liu B; Ma QL; Peng J
Curr Drug Targets; 2014; 15(10):948-55. PubMed ID: 25163552
[TBL] [Abstract][Full Text] [Related]
11. STA-55, an Easily Accessible, Broad-Spectrum, Activity-Based Aldehyde Dehydrogenase Probe.
Koenders STA; van Rooden EJ; van den Elst H; Florea BI; Overkleeft HS; van der Stelt M
Chembiochem; 2020 Jul; 21(13):1911-1917. PubMed ID: 31985142
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by chlorpropamide analogues.
Rekha GK; Devaraj VR; Sreerama L; Lee MJ; Nagasawa HT; Sladek NE
Biochem Pharmacol; 1998 Feb; 55(4):465-74. PubMed ID: 9514081
[TBL] [Abstract][Full Text] [Related]
13. Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism.
Klyosov AA; Rashkovetsky LG; Tahir MK; Keung WM
Biochemistry; 1996 Apr; 35(14):4445-56. PubMed ID: 8605194
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity.
Yang SM; Martinez NJ; Yasgar A; Danchik C; Johansson C; Wang Y; Baljinnyam B; Wang AQ; Xu X; Shah P; Cheff D; Wang XS; Roth J; Lal-Nag M; Dunford JE; Oppermann U; Vasiliou V; Simeonov A; Jadhav A; Maloney DJ
J Med Chem; 2018 Jun; 61(11):4883-4903. PubMed ID: 29767973
[TBL] [Abstract][Full Text] [Related]
15. Rat liver constitutive and phenobarbital-inducible cytosolic aldehyde dehydrogenases are highly homologous proteins that function as distinct isozymes.
Kathmann EC; Naylor S; Lipsky JJ
Biochemistry; 2000 Sep; 39(36):11170-6. PubMed ID: 10998257
[TBL] [Abstract][Full Text] [Related]
16. Aldehyde dehydrogenases and cancer stem cells.
Xu X; Chai S; Wang P; Zhang C; Yang Y; Yang Y; Wang K
Cancer Lett; 2015 Dec; 369(1):50-7. PubMed ID: 26319899
[TBL] [Abstract][Full Text] [Related]
17. Identification of cancer-type specific expression patterns for active aldehyde dehydrogenase (ALDH) isoforms in ALDEFLUOR assay.
Zhou L; Sheng D; Wang D; Ma W; Deng Q; Deng L; Liu S
Cell Biol Toxicol; 2019 Apr; 35(2):161-177. PubMed ID: 30220009
[TBL] [Abstract][Full Text] [Related]
18. Aldehyde dehydrogenases and their role in carcinogenesis.
Lindahl R
Crit Rev Biochem Mol Biol; 1992; 27(4-5):283-335. PubMed ID: 1521460
[TBL] [Abstract][Full Text] [Related]
19. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde.
Dockham PA; Lee MO; Sladek NE
Biochem Pharmacol; 1992 Jun; 43(11):2453-69. PubMed ID: 1610409
[TBL] [Abstract][Full Text] [Related]
20. Development of a Novel Multi-Isoform ALDH Inhibitor Effective as an Antimelanoma Agent.
Dinavahi SS; Gowda R; Gowda K; Bazewicz CG; Chirasani VR; Battu MB; Berg A; Dokholyan NV; Amin S; Robertson GP
Mol Cancer Ther; 2020 Feb; 19(2):447-459. PubMed ID: 31754071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
